Qlucore AB (publ)

ST:NOVKAN USA Biotechnology
Market Cap
$1.20 Million
Skr13.48 Million SEK
Market Cap Rank
#35892 Global
#11681 in USA
Share Price
Skr0.11
Change (1 day)
+17.05%
52-Week Range
Skr0.08 - Skr0.23
All Time High
Skr0.23
About

Novakand Pharma AB (publ) develops drugs for inflammatory diseases and cancer in Sweden and internationally. The company is developing small molecule drug candidates KAND567, which is in phase IIa clinical trial for inflammatory heart disease following infarction, as well as KAND145, which is in phase II study in healthy subjects to document desired dose levels against cancer; and Phase IIa study… Read more

Qlucore AB (publ) (NOVKAN) - Cash Flow Conversion Efficiency

Latest cash flow conversion efficiency as of December 2025: -0.411x

Based on the latest financial reports, Qlucore AB (publ) (NOVKAN) has a cash flow conversion efficiency ratio of -0.411x as of December 2025.

Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-6.19 Million) by net assets (Skr15.06 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Qlucore AB (publ) - Cash Flow Conversion Efficiency Trend (2010–2025)

This chart illustrates how Qlucore AB (publ)'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.

Qlucore AB (publ) Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Qlucore AB (publ) ranked by their cash flow conversion efficiency.

Annual Cash Flow Conversion Efficiency for Qlucore AB (publ) (2010–2025)

The table below shows the annual cash flow conversion efficiency of Qlucore AB (publ) from 2010 to 2025.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 Skr15.06 Million Skr-30.29 Million -2.011x -114.02%
2024-12-31 Skr62.30 Million Skr-58.53 Million -0.940x +19.56%
2023-12-31 Skr47.66 Million Skr-55.67 Million -1.168x -162.54%
2022-12-31 Skr106.91 Million Skr-47.56 Million -0.445x -23.54%
2021-12-31 Skr122.54 Million Skr-44.12 Million -0.360x +33.24%
2020-12-31 Skr72.28 Million Skr-38.99 Million -0.539x +71.77%
2019-12-31 Skr17.42 Million Skr-33.29 Million -1.911x -41.51%
2018-12-31 Skr33.36 Million Skr-45.04 Million -1.350x +2.37%
2017-12-31 Skr38.71 Million Skr-53.54 Million -1.383x -256.36%
2016-12-31 Skr59.52 Million Skr-23.10 Million -0.388x +58.81%
2015-12-31 Skr21.93 Million Skr-20.66 Million -0.942x -34.58%
2014-12-31 Skr27.29 Million Skr-19.11 Million -0.700x -99.93%
2013-12-31 Skr18.96 Million Skr-6.64 Million -0.350x +92.89%
2012-12-31 Skr5.50 Million Skr-27.08 Million -4.925x -449.52%
2011-12-31 Skr25.90 Million Skr-23.21 Million -0.896x -75.76%
2010-12-31 Skr11.07 Million Skr-5.64 Million -0.510x --